Fibromyalgia Drug Delayed

San Diego’s Cypress Bioscience (NASDAQ: CYPB) and New York’s Forest Laboratories (NYSE: FRX) said Friday their launch of a new drug for treating fibromyalgia, which was expected to be available this month, has been delayed by several months. The companies now say they expect to ship the recently approved drug milnacipran HCL (Savella) to wholesalers and pharmacies by mid-2009.

Bruce V. Bigelow was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Follow @bvbigelow

Trending on Xconomy